Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) - Stock Overview & Analysis

Search your stocks

Profile

GLAXOGlaxosmithkline Pharmaceuticals Ltd.

₹2743-0.45%

Market Cap

₹47,510.76 Cr

Stock P/E

51.70

ROCE

46.49%

ROE

33.43%

Book Value

₹105.47

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Institution

Public

Others

Financials

YoY Net Sales

EPS Growth

Operating Margin

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Sector Leader

Glaxosmithkline Pharmaceuticals Ltd. stands out among its peers with strong profitability metrics, particularly in ROE and EPS growth. While some competitors exhibit higher revenue growth, GSK maintains a solid balance of growth and profitability, positioning it well within the pharmaceuticals sector.

Key Points

• GlaxoSmithKline leads in ROE and EPS growth, indicating strong profitability.
• Mankind Pharma shows impressive revenue growth but is slightly overvalued at its current PE ratio.
• Divi's Laboratories is facing significant challenges with declining revenue growth over the past three years.
• Cipla is undervalued compared to its peers with a low PE and strong revenue growth.

Top Performers

Glaxosmithkline Pharmaceuticals Ltd.

Highest ROE (33.43%) and strong EPS growth (54.76) indicate robust profitability.

Cipla Ltd.

Strong revenue growth (YoY: 13.28%) and low valuation multiples (PE: 23.73) make it a value pick.

Dr. Reddy's Laboratories Ltd.

Solid profitability with high ROE (21.76%) and low PE (15.50) suggest good value.